Premium
Lansoprazole‐sulfide, pharmacokinetics of this promising anti‐tuberculous agent
Author(s) -
Mdanda Sipho,
Baijnath Sooraj,
Shobo Adeola,
Singh Sanil D.,
Maguire Glenn E.M.,
Kruger Hendrik G.,
Arvidsson Per I.,
Naicker Tricia,
Govender Thavendran
Publication year - 2017
Publication title -
biomedical chromatography
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.4
H-Index - 65
eISSN - 1099-0801
pISSN - 0269-3879
DOI - 10.1002/bmc.4035
Subject(s) - lansoprazole , pharmacokinetics , chemistry , metabolite , in vivo , pharmacology , mycobacterium tuberculosis , oral administration , active metabolite , chromatography , minimum inhibitory concentration , in vitro , tuberculosis , medicine , biochemistry , omeprazole , pathology , biology , microbiology and biotechnology
Lansoprazole (LPZ) is a commercially available proton‐pump inhibitor whose primary metabolite, lansoprazole sulfide (LPZS) was recently reported to have in vitro and in vivo activity against Mycobacterium tuberculosis . It was also reported that a 300 mg kg −1 oral administration of LPZS was necessary to reach therapeutic levels in the lung, with the equivalent human dose being unrealistic. A validated liquid chromatography–tandem mass spectrometric method (LC–MS/MS) for the simultaneous quantification LPZ and LPZS in rat plasma and lung homogenates was developed. We administered 15 mg kg −1 oral doses of LPZ to a healthy rat model to determine the pharmacokinetics of its active metabolite, LPZS, in plasma and lung tissue. We found that the LPZS was present in amounts that were below the limit of quantification. This prompted us to administer the same dose of LPZS to the experimental animals intraperitoneally (i.p.). Using this approach, we found high concentrations of LPZS in plasma and lung, 7841.1 and 9761.2 ng mL −1 , respectively, which were significantly greater than the minimum inhibitory concentration (MIC) for Mycobacterium tuberculosis. While oral and i.p. administration of LPZ resulted in significant concentrations in the lung, it did not undergo sufficient cellular conversion to its anti‐TB metabolite. However, when LPZS itself was administered i.p., significant amounts penetrated the tissue. These results have implications for future in vivo studies exploring the potential of LPZS as an anti‐TB compound.